Interactions : אינטראקציות

4.5   Interaction with other medicinal products and other forms of interaction

Since alpha-interferons alter cellular metabolism, the potential to modify the activity of other drugs exists.
In a small study, Roferon-A was shown to have an effect on specific microsomal enzyme systems. The clinical relevance of these findings is unknown.

Alpha-interferons may affect the oxidative metabolic process; this should be borne in mind when prescribing concomitant therapy with drugs metabolised by this route. However, as yet no specific information is available.

Roferon-A has been reported to reduce the clearance of theophylline.

As Roferon-A may affect central nervous system functions, interactions could occur following concurrent administration of centrally-acting drugs. The neurotoxic, haematotoxic or cardiotoxic effects of previously or concurrently administered drugs may be increased by interferons.

Combination therapy with ribavirin: Also see ribavirin labelling if interferon alfa-2a is to be administered in combination with ribavirin in patients with chronic hepatitis C.

Results from a controlled clinical study in renal cancer patients demonstrated no significant effect of bevacizumab (Avastin) on the pharmacokinetics of interferon alfa-2a (Roferon-A).